A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
复制标题
DOI：
10.1056/nejm199704243361704
复制
发表时间：
1997-04-24
影响因子：
158.5
通讯作者：
Thal, LJ
中科院分区：
文献类型：
--
作者：
Sano, M;Ernesto, C;Thal, LJ
背景 有证据表明，增加大脑儿茶酚胺水平并防止氧化损伤的药物或维生素可能会减少神经元损伤并减缓阿尔茨海默病的进展。方法我们对中度阿尔茨海默病患者进行了一项双盲、安慰剂对照、随机、多中心试验。共有 341 名患者接受选择性单胺氧化酶抑制剂司来吉兰（每天 10 毫克）、α-生育酚（维生素 E，每天 2000 IU）、司来吉兰和 α-生育酚或安慰剂治疗两年。主要结局是发生以下任何情况的时间：死亡、住院、丧失进行基本日常生活活动的能力或严重痴呆（定义为临床痴呆评级为 3）。 结果 尽管随机分配，安慰剂组的简易精神状态检查基线评分高于其他三组，并且该变量高度预测主要结局（P
Background There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease.Methods We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3).Results Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P